Treatment of Osteoarthritis With Celecoxib, a Cyclooxygenase-2 Inhibitor: A Randomized Controlled Trial

摘要: Objective To compare the efficacy and safety of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, with those naproxen, nonsteroidal anti-inflammatory drug (NSAID), placebo in treatment osteoarthritis knee. Methods In this multicenter, randomized, double-blind, placebo-controlled trial, 1003 patients symptomatic knee were randomly assigned to receive celecoxib at doses 50, 100, or 200 mg twice day; 500 for 12 weeks. Patients evaluated standard measures 2 7 days after discontinuing previous NSAID analgesic therapy 2, 6, weeks study drug. Results Celecoxib led significant improvement signs symptoms as determined by all measures. Significant pain relief occurred within initiation treatment, maximum activity, evident weeks, was sustained throughout 12-week study. All efficacious compared placebo, although 50-mg twice-daily dosage regimen minimally effective. The higher (100 day) similarly efficacious, magnitude observed these dosing regimens comparable that seen naproxen dose day. well tolerated. Conclusion COX-2 inhibition is an effective approach osteoarthritis, clinical naproxen.